Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given an average recommendation of "Buy" by the eight research firms that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $6.63.

TSHA has been the subject of a number of analyst reports. JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reissued a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock traded up $0.24 during trading hours on Friday, hitting $3.24. 2,242,531 shares of the company were exchanged, compared to its average volume of 8,068,820. The business has a 50-day moving average of $2.06 and a 200-day moving average of $2.39. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $664.02 million, a price-to-earnings ratio of 5.14 and a beta of 0.44.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $28,000. Principal Financial Group Inc. purchased a new position in Taysha Gene Therapies during the 2nd quarter valued at about $48,000. China Universal Asset Management Co. Ltd. raised its position in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock worth $79,000 after acquiring an additional 17,446 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Taysha Gene Therapies in the third quarter valued at about $85,000. Finally, Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at approximately $97,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.